Movement Disorders

Movement disorder specialists reflected on a decade of community, research, and career support in-person and online for members of the Women Neurologists Group. [WATCH TIME: 7 minutes]

Panelists discuss the growing role of continuous infusion therapies in managing advanced Parkinson disease, highlighting their effectiveness in reducing motor fluctuations and dyskinesia, improving quality of life, and supporting individualized, long-term treatment strategies amid ongoing advancements in drug delivery and patient selection.

Movement disorder specialists talked about how the 4th Annual Women in Neurology Conference will offer educational updates, career development, and networking opportunities for women across neurology. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Movement disorder specialists reflected on the community’s growth over the past decade in the Women Neurologists Group and shared program highlights of the group’s upcoming conference. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 12, 2025.

The director of the Neuroethics Program at Cleveland Clinic discussed ethics training, shared decision-making, and safeguards in guiding patients, families, and clinicians through complex clinical research decisions. [WATCH TIME: 3 minutes]

Tamara Kaplan, MD, vice chair of education for the department of neurology at Mass General Brigham, shares insights on evolving neurology education, highlighting her framework for supporting clinician educators and the growing recognition of education as a career path.

Teva's emrusolmin receives FDA fast track designation as a potential breakthrough treatment for multiple system atrophy, targeting neurodegeneration.

Catch up on any of the neurology news headlines you may have missed in August 2025, compiled into 1 place by the NeurologyLive® team.

A recent trial shows that 3 infusions of stem cells significantly enhance motor function in Parkinson patients, highlighting the need for further research.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 5, 2025.

Panelist discusses how distinguishing between dyskinesia (choreiform, dance-like movements) and tremor in Parkinson disease is crucial for treatment decisions, as modern therapeutic options including extended-release amantadine, continuous subcutaneous delivery systems, and advanced formulations can now effectively manage both motor fluctuations and troublesome dyskinesias simultaneously.

The director of the Neuroethics Program at Cleveland Clinic discussed the evolving role of ethics in neurological clinical trials, highlighting skill development, safeguards, and patient-centered decision-making.

The physician assistant specializing in Parkinson disease talked about the shared decision-making process when discussing advanced therapies for movement disorder care with patients. [WATCH TIME: 3 minutes]

The nurse practitioner in the Center for Movement Disorders & Neurorestoration at the University of Florida discussed clinical experiences with deep brain stimulation for atypical MS tremor and PD. [WATCH TIME: 5 minutes]

The director of the Movement Disorders Clinic at Houston Methodist Hospital outlined a stepwise approach for identifying, managing, and treating hallucinations in patients with Parkinson disease. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the link between iRBD and neurodegeneration.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 29, 2025.

The director of the Norman Fixel Institute for Neurological Diseases at UF Health talked about prevention, understanding disease mechanisms, and creating a patient-centered care model in Parkinson disease. [WATCH TIME: 5 minutes]

A recent Canadian study reported similar trends in polysomnography and positive airway pressure initiation over a decade between patients with Parkinson disease and matched controls.

A pivotal phase 3 study explores ampreloxetine's potential to treat neurogenic orthostatic hypotension in multiple system atrophy patients, aiming for FDA approval.

The director of the Norman Fixel Institute for Neurological Diseases at UF Health highlighted the need for equitable, worldwide access to levodopa for patients with Parkinson disease. [WATCH TIME: 6 minutes]